Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Splenomegaly 1Primary Myelofibrosis 1Leukemia 1Anemia 1

Interventions

Epoetin Alfa 9Darbepoetin alfa 5epoetin beta 3telapristone acetate 2fludarabine phosphate 2fludarabine 2Cyclophosphamide 2Carboplatin 2Busulfan 2AP 1903 reagent 2ACE-011 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1vactosertib 1trametinib 1thymoglobulin 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1peginesatide 1palbociclib 1olaparib 1niraparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1hematide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anemia × ON 01910 × Clear all
NCT02730884 2020-08-07

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 6 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Splenomegaly, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡